| CD19/BCMA targeted CAR T-cells / Shanghai Yake Biotech |
NCT05030779: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Systemic Lupus Erythematosus, Autoimmune Diseases | 03/22 | 09/22 | | |
NCT04603872: CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies |
|
|
| Recruiting | 1 | 120 | RoW | CD19/BCMA Targeted CAR T-cells and dasatinib, Administration of CD19/BCMA Targeted CAR T-cells and dasatinib, CD19/BCMA Targeted CAR T-cells, CD19/BCMA Targeted CAR T-cells infusion | Zhejiang University, Yake Biotechnology Ltd. | Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphocytic Leukaemia Refractory, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory | 11/23 | 11/26 | | |
NCT05263817: A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis |
|
|
| Recruiting | 1 | 75 | RoW | CD19/BCMA CAR T-cells, CD19/BCMA CAR T-cells injection | Zhejiang University, Yake Biotechnology Ltd. | POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, Vasculitis | 10/24 | 10/24 | | |
NCT05085444: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Scleroderma, Autoimmune Diseases | 10/24 | 10/24 | | |
NCT05085431: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Sjogren's Syndrome, Autoimmune Diseases | 11/24 | 11/24 | | |
NCT05085418: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Immune Nephritis, Autoimmune Diseases, Lupus Nephritis | 11/24 | 11/24 | | |
